Project Grant K99EB039138
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded The Regents of the University of California, doing business as University of California, Berkeley, a Project Grant totaling $361,952 under the Biomedical Research and Research Training program (CFDA 93.859) effective September 1, 2025, with a completion date of June 30, 2030. This award funds fundamental research aimed at mapping and predicting the sequence-function landscape of biomedically...
- Federal Project Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Leland Stanford Junior University a $460,349 Project Grant effective May 8, 2026, through February 28, 2030, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award supports development of a cell-based macromolecule delivery platform termed "TROGOCYTOSIS-based Transfer and Functional Effector...
- Federal Grant Award Summary The University of California, San Francisco received a $445,049 Project Grant award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, through March 31, 2031. This research initiative develops innovative lipid nanoparticle (LNP) formulations designed to achieve cell-type-specific delivery of programmable RNA therapeutics. The project integrates bio-inspired...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded UC Berkeley $119,907 under the Biomedical Research and Research Training program (CFDA 93.859) for a two-year project period (August 1, 2025 – July 31, 2027). This Project Grant funds fundamental research to advance understanding of TnpB, a compact transposon-encoded RNA-guided endonuclease with significant potential for genome-editing applications. The research delivers three primary products: (1) a...
- Federal Grant Award Summary The University of California, Berkeley received a $617,574 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 9, 2026, with a completion date of February 28, 2030. This award supports fundamental research investigating the mechanisms of site-specific non-LTR retrotransposon mobility and transgene insertion in animal genomes. The research focuses on...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.476 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) for the period September 15, 2025, through August 31, 2028. The award supports research titled "Engineering Enhanced Erythropoiesis for Red Blood Cell Disorders," which aims to develop novel genome engineering approaches to enhance red blood...
- Federal Grant Award Summary The University of California, San Diego received a Project Grant award of $376,498 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, with a completion date of July 31, 2030. The award funds research into active genetic systems—CRISPR-based genetic technologies that bypass traditional inheritance patterns to enable self-propagating genetic elements known...
- Federal Grant Award Summary The National Human Genome Research Institute (NHGRI) awarded a $249,000 Project Grant to the Regents of the University of California at Riverside on September 23, 2025, under the Human Genome Research program (CFDA 93.172). This award supports the development and application of laser particles (LPs)-based technology for spatiotemporal and dynamic single-cell multiomics research. The project will create a novel "dual-barcoding" cell tracking system...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $2,656,684 to The Regents of the University of California, San Francisco on February 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This award will support research through January 31, 2031, focused on discovering and validating delivery vectors for gene therapies and biologics targeting central nervous...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a Project Grant totaling $120,393 to The Regents of the University of California, Berkeley, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award, effective May 1, 2026, through April 30, 2028, supports development of engineered delivery vehicles for genome editing enzymes that can be produced and distributed within the body to amplify editing efficiency across multiple cell types. The research addresses critical limitations in delivering CRISPR-Cas9 genome editing tools to hematopoietic stem cells and other cell types outside the liver by enabling initially-targeted cells to transiently produce and propagate editing enzymes to neighboring cells through vesicles. The project deliverables include: (1) development of single nucleic acid molecules encoding enveloped delivery vehicles (EDVs) derived from lentivirus-based lipid vesicles; (2) establishment of cell-type-specific targeting and uptake methodologies using surface-displayed fusogens and antibodies; and (3) in vivo delivery systems using EDV-encoding plasmids to amplify genome editing efficacy. Preliminary hydrodynamic injection studies in mice demonstrated amplified genome editing efficiencies compared to Cas9-only controls, establishing proof-of-concept for this technology-driven biomedical engineering approach with potential to transform cell and gene therapies for genetic diseases including sickle cell disease.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $120.4k | 4/27/26 |